A phase II study of bevacizumab (Avastin) and erlotinib (Tarceva) in combination with FOLFOX [fluorouracil + folinic acid + oxaliplatin] for patients with untreated metastatic colorectal cancer

Trial Profile

A phase II study of bevacizumab (Avastin) and erlotinib (Tarceva) in combination with FOLFOX [fluorouracil + folinic acid + oxaliplatin] for patients with untreated metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Bevacizumab; Erlotinib; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2008 Updated from NCT record (DMS 11-01-08).
    • 20 Dec 2007 Status changed from in progress to completed.
    • 19 Jan 2007 Status changed from recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top